Shanghai Reseat Medical Technology Acquires 16% Stake of U.S. Bionic Eye Technologies
This article was originally published in PharmAsia News
Hainan Haiyao announced that its subsidiary, Shanghai Reseat Medical Technology, invested and acquired 16% stake of U.S. Bionic Eye Technologies by spending no more than $3 million.
You may also be interested in...
Rather than rail at China, senators explored causes and corrective actions for drug shortages that are closer to home.
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.